Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
RécupérationPréclinique uniquement

TB-500 + BPC-157

Recherche publiée et base de preuves

One published study has directly tested BPC-157 and TB-500 together against each agent alone, and it found no additive benefit. Beyond that single rat Achilles tendon experiment and one retrospective human chart review in which some knee-pain patients received BPC 157 combined with thymosin beta-4, there is no peer-reviewed evidence for the combination. All other support is component-level: the two peptides have separate preclinical literatures that have been reviewed together in sports-medicine journals, but no synergy has been demonstrated in any model.

En bref
  • BPC-157 et TB-500 sont deux peptides examinés ensemble dans des revues de médecine sportive.
  • Une étude chez le rat n'a trouvé aucun bénéfice additif de la combinaison pour les tendons.
  • Aucun essai humain n'a testé la combinaison et aucune synergie n'a été démontrée.

9 études · 6 depuis 2023 · plus récente 2026

Études citées
9
Publiées 2023+
6
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • combination versus monotherapy tendon healing
  • convergence on shared downstream repair pathways
  • absence of demonstrated synergy
  • sports medicine gray-market peptide stacking

Les preuves

9 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Revue systématique2026

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine

    Tewari K, et al. · Am J Sports Med · PRISMA-guided scoping review of six peptides including BPC-157 and TB-500 against musculoskeletal tissue outcomes

    Sixty-seven percent of the identified literature used preclinical animal models and human clinical studies were limited to a handful of investigations. The review reported each compound separately and identified no combination trials.

  2. 02Revue systématique2025

    Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

    Vasireddi N, et al. · HSS J · systematic review of the BPC-157 musculoskeletal literature

    The review synthesised preclinical evidence for fracture, tendon, ligament and muscle healing and recorded the compound's lack of FDA approval and its prohibited status in professional sport. No combination studies were included.

  3. 03Clinique humaine2021

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B · Altern Ther Health Med · retrospective chart review at a single private clinic, 2019-2020; 17 patients given intra-articular BPC 157 alone or combined with thymosin beta-4, telephone follow-up in 16

    The review recorded self-rated pain change after intra-articular injection of BPC 157 alone or with thymosin beta-4. It used no validated outcome instruments and no control group, and did not separate combination recipients from monotherapy recipients in a way that permits inference about combination effect. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  4. 04Animal in vivo2026

    Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

    Biçer O, et al. · Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats in 4 groups of 8 including a dedicated BPC-157 + TB-500 combination arm; intraperitoneal dosing for 4 weeks

    This is the only published study to test the combination against each peptide alone. The combination group showed significantly lower total Movin scores than controls, but the authors stated explicitly that combined treatment did not confer additional benefit compared with either agent alone, and hypothesised convergence on shared downstream pathways.

  5. 05Animal in vivo2021

    Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

    Japjec M, et al. · Biomedicines · rat myotendinous junction defect created by dissecting the quadriceps tendon from the quadriceps muscle

    BPC 157 improved macroscopic, microscopic, biomechanical and functional outcomes at the myotendinous junction, with associated changes in eNOS and COX-2 mRNA and in nitric oxide levels. Component-level evidence only.

  6. 06Animal in vivo1999

    Thymosin beta4 accelerates wound healing

    Malinda KM, et al. · J Invest Dermatol · rat full-thickness dermal wound model; topical or intraperitoneal thymosin beta4

    Thymosin beta4 increased re-epithelialisation by 42 percent at 4 days and up to 61 percent at 7 days versus saline controls, with increased collagen deposition and angiogenesis. Component-level evidence only.

  7. 07Revue2026

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, et al. · Am J Sports Med · narrative review of injectable peptide therapies including BPC-157, TB-4 and TB-500

    The review found BPC-157 showed potential in tendon and muscle repair that is largely unvalidated in human trials, noted the single human knee case series and its methodological limitations, and stated that TB-4 and TB-500 promoted angiogenesis and tissue repair in preclinical models while human orthopaedic data are lacking.

  8. 08Revue2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, et al. · Sports Med · narrative review of approved and unapproved peptides marketed direct to patients, covering both BPC-157 and Tb4/TB-500

    The review reported favourable animal-model tissue repair outcomes for several unapproved peptides alongside scarce human safety data, and discussed placebo effects and social media amplification as mediators of perceived efficacy. It did not identify combination evidence.

  9. 09Revue2026

    Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.

    Moiz A, et al. · Mo Med · narrative clinical review of unregulated injectable peptides

    Named both BPC-157 and TB-500 among unapproved peptides lacking established human safety profiles and described risks of contamination, impurities, inaccurate dosing, pathological angiogenesis and carcinogenesis.

    Résultat de sécurité signalé. Authors flagged contamination, impurities and theoretical angiogenesis/carcinogenesis risks for both unregulated peptides.

Limites

Ce que ces preuves n'établissent pas.

The single controlled experiment of this combination found no additive benefit over monotherapy, and it was a four-week exploratory rat study with eight animals per group. There is no human trial of the combination, no dose-optimisation work, no long-term follow-up, and no published evidence of pharmacological synergy in any tissue.

Questions courantes sur la recherche.

Why are BPC-157 and TB-500 studied together?

The two peptides have separate preclinical literatures that converge on overlapping tissue-repair endpoints, and sports-medicine reviews have appraised them side by side for that reason. That convergence is the stated rationale for pairing them rather than a demonstrated pharmacological interaction. No published work has shown synergy between the two in any model or species.

Has the BPC-157 and TB-500 combination been tested against each peptide alone?

Once. A 2026 experiment in 32 male Sprague-Dawley rats with Achilles tendon transection and repair compared a control group, BPC-157 at 10 ug/kg/day, TB-500 at 60 ug/kg/day and a dedicated combination arm, with intraperitoneal dosing over four weeks. The combination group showed significantly lower total Movin scores than controls, but the authors stated explicitly that combined treatment did not confer additional benefit over either peptide given alone. The TB-500 group additionally showed a significantly higher maximum load to failure.

Is there any human evidence for the combination?

There is no human trial of the combination. The only human record is a 2021 retrospective chart review at a single private clinic covering 17 patients who received intra-articular BPC 157 alone or combined with thymosin beta-4, with telephone follow-up in 16. That review used no validated outcome instruments and no control group, and did not separate combination recipients from monotherapy recipients in a way that would allow the combination to be assessed.

Disponible dans notre catalogue

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.